On April 1, 2024, the American company
Sutro Biopharma, listed on NASDAQ, and the well-known French pharmaceutical company
Ipsen, formalized a global exclusive licensing agreement. This significant deal pertains to Sutro's experimental Antibody-Drug Conjugate (ADC),
STRO-003. In the agreement, Ipsen commits to an upfront payment of $90 million to Sutro, with the potential for up to $900 million in additional milestone payments. This partnership marks Ipsen's first extensive foray into the ADC field.
STRO-003 is a cutting-edge ADC targeting
Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). This candidate employs
exatecan (iexabepilone) as its payload, connected via a β-glucuronidase-cleavable linker. Beyond STRO-003, Sutro is advancing other ADC candidates, including those targeting
FRa and
CD74, which are in clinical development. Additionally, Sutro has a TF-targeting ADC in preclinical stages. The company is also in partnership with
Astellas to develop immunostimulatory ADCs (iADCs), currently in preclinical research phases.
In the ROR1 ADC realm, other prominent candidates have emerged. Notable among them are
CS5001 from
LegoChem in collaboration with
Cornerstone,
Zilovertamab Vedotin (MK-2140) from the partnership between
Merck and
VelosBio, a bispecific ADC from
Bolt Biotherapeutics, and
NBE-002 from the collaboration between
BI and
NBE Therapeutics. Recent clinical findings from Cornerstone on CS5001 indicate it has shown significant anti-
tumor activity and a favorable safety profile across various types of
solid tumors and
blood cancers.
This transaction not only underscores the tremendous potential of ADC technology in targeted cancer treatments but also illuminates the vigorous competition among global pharmaceutical firms in this domain. A detailed examination of the current clinical and market dynamics surrounding ROR1 ADCs will enhance our comprehension of the evolving trends in the development of innovative therapies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
